摘要
免疫检查点抑制剂已被证实可显著提高多种恶性肿瘤患者的生存率,因此需要寻找有效的疗效预测指标来指导免疫治疗。肺免疫预后指数(LIPI)是近期发展起来的预测非小细胞肺癌免疫治疗疗效的新指标。基线LIPI能够识别免疫治疗潜在获益人群,是一种方便有效的预后预测指标。
Immune checkpoint inhibitors have demonstrated the ability to significantly improve survival across a range of cancers.So predictive markers are required to guide treatment decisions.The lung immune prognostic index(LIPI)is recently developed to predict immune checkpoint inhibitors(ICIs)treatment outcomes for non-small cell lung cancer.The pre-treatment LIPI is a convenient prognostic marker able to idenjpgy ICIs-treated patient groups with significantly different survival and response outcomes.
作者
张爱霞
孙亚红
Zhang Aixia;Sun Yahong(Second Department of Oncology,Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences),Jinan 250031,China)
出处
《国际肿瘤学杂志》
CAS
2020年第5期301-303,共3页
Journal of International Oncology
关键词
癌
非小细胞肺
预后
免疫检查点抑制剂
肺免疫预后指数
Carcinoma
non-small-cell lung
Prognosis
Immune checkpoint inhibitor
Lung immune prognostic index
